Pro-Pharmaceuticals submits data to the FDA

Pro-Pharmaceuticals Inc. of Newton said today it has submitted data to federal regulators to support a plan for its Davanat to be considered as part of chemotherapies for the treatment of advanced solid tumors and breast and colorectal cancers.

Specifically, Pro-Pharmaceuticals said it has submitted clinical and pre-clinical data to the US Food and Drug Administration for a pre-Investigational New Drug (IND) meeting that is scheduled for Oct. 8.

Pro-Pharmaceuticals said in a press release: "The company plans to present the development plan to the FDA for an anti-hypoxia drug to be used in combination with Davanat and 5-FU to treat advanced solid tumors, including head and neck, breast and colorectal cancers. The plan is in direct response to current studies indicating tumors resistance to chemotherapy and radiation are linked to hypoxia."

Davanat is a compound that Pro-Pharmaceuticals hopes can be brought to market with multiple chemotherapy drugs.
(By Chris Reidy, Globe staff)